Valuation dashboard for Alkermes plc (ALKS) with P/E 112.07, P/B 4.16, EV/EBITDA N/A and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Valuation Ratios
| P/E Ratio | 112.07 |
| Price / Book | 4.16 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| TAK | Takeda Pharmaceutical Company Limited | $59.4B | 51.19 | 1.21 | 2.6% |
| TEVA | Teva Pharmaceutical Industries Limited | $45.0B | 61.47 | 5.82 | 17.8% |
| HLN | Haleon plc | $40.5B | 18.64 | 1.84 | 9.9% |
| 0M3Q.L | Zoetis Inc. | $35.4B | |||
| ZTS | Zoetis Inc. | $30.6B | 11.99 | 9.67 | 69.3% |
| HLN.L | Haleon plc | $29.4B | 18.73 | 1.85 | 9.9% |
| 0SAN.L | Sandoz Group AG | $28.3B | 52.81 | 3.84 | 7.0% |
Price
| Price | $46.07 |
| Market Cap | $7.7B |
| Exchange | NASDAQ |
| Country | IE |
Profitability
| Gross Margin | 84.56% |
| Operating Margin | 7.03% |
| Net Margin | 3.97% |
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ALKS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks